GENinCode UK Ltd. (GB:GENI) has released an update.
GENinCode UK Ltd. presented new findings at the ESC Preventive Cardiology Congress, showing that their CARDIO inCode-Score® effectively identifies individuals at high risk for coronary heart disease (CHD) by evaluating genetic and LDL-C levels. The study suggests that people with high polygenic risk may benefit more from lipid-lowering therapies, and those with elevated CARDIO inCode-Scores should maintain lower LDL-C levels. This reinforces the value of combining polygenic risk scores with traditional assessments for optimizing CHD prevention strategies.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.
